Using GLP-1 therapy to improve glucose tolerance in cystic fibrosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of dulaglutide, a GLP-1 agonist, on improving insulin secretion and glucose tolerance in adults with cystic fibrosis-related diabetes. The study aims to determine if weekly administration of this medication can enhance early-phase insulin secretion during a mixed-meal tolerance test. Participants will include individuals diagnosed with cystic fibrosis and pancreatic insufficiency who exhibit abnormal glucose tolerance. The trial will assess the potential of this intervention to delay or prevent the progression of diabetes in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Male or female, aged ≥18 years on date of consent
* 2\. Confirmed diagnosis of CF, defined by positive sweat test or Cystic Fibrosis transmembrane conductance regulator (CFTR) mutation analysis according to Cystic Fibrosis Foundation (CFF) diagnostic criteria.
* 3\. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.
* 4\. Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.

  1. There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg/dL)
  2. Individuals with CFRD and fasting hyperglycemia (defined as above or by the use of basal insulin therapy) must also have a HbA1c ≤8% and a random (non-fasting) C-peptide ≥1.2 ng/mL17; enrollment of this subgroup will be limited to n =10.
* 5\. Ability to take subcutaneous medication and be willing to adhere to the weekly administration regimen and complete study specific procedures (MMTT)
* 6\. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of dulaglutide or observation administration; oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable

Exclusion Criteria:

* 1\. BMI \<19 kg/m2
* 2\. Presence of first-degree atrioventricular block or other evidence for cardiac conduction system or structural heart defects
* 3\. Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment
* 4\. Known allergic reactions to any GLP-1 agonist, and any history of severe hypersensitivity reactions (anaphylaxis or angioedema)
* 5\. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)
* 6\. Pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to study procedures
* 7\. Gastrointestinal symptom exacerbation defined by current nausea/vomiting or diarrhea
* 8\. Established diagnosis of non-CF diabetes (e.g. type 1 diabetes) or CFRD with fasting hyperglycemia (fasting glucose ≥126 mg/dL \[use of prandial insulin or repaglinide will be permitted\])
* 9\. History of clinically symptomatic pancreatitis within the last year
* 10\. Prior lung, liver or other solid organ transplant
* 11\. Severe CF liver disease, as defined by the presence of portal hypertension
* 12\. History of fundoplication-related dumping syndrome
* 13\. Hemoglobin \<10 g/dL, within 90 days of study procedures or at screening
* 14\. Abnormal renal function, within 90 days of study procedures or at screening; defined as creatinine \>2x upper limit of normal (ULN) or potassium \>5.5mEq/L on non-hemolyzed specimen
* 15\. History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject

Where it's running

• Children's Hospital of Colorado
  Aurora, Colorado, United States Recruiting
• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Michael R Rickels, MD, MS — University of Pennsylvania
• Study coordinator: Paola Alvarado, MS
• Email: Paola.Alvarado@pennmedicine.upenn.edu
• Phone: 215-746-2081

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding how incretin hormones affect insulin in cystic fibrosis patients

  This study tests if giving incretin hormones can help improve insulin production in cystic fibrosis patients who have diabetes.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT01851694

• New virtual care pathway for older adults with chronic diseases

  A teleconsultation-based care pathway for adults 60+ with hypertension, diabetes, or dyslipidemia to see if it’s feasible and cost-saving in Malaysian primary care compared with usual clinic visits.

  Recruiting National University of Malaysia · Kuala Lumpur · NCT07843238

• Benefits of Retained Insulin for Good Health in Diabetes

  This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.

  Recruiting at 4 sites Royal Devon and Exeter NHS Foundation Trust · Truro, Cornwall and 3 other locations · NCT07828626

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

• Myokines in metabolic and endocrine diseases linked to sarcopenia

  This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe · NCT07703683

• Miniature breath sensors to detect hypo- and hyperglycemia in young people with diabetes

  A small breath-sensor device will try to see if specific breath compounds can signal low or high blood sugar in youths with diabetes.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07696273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.